A 01 - IC 01

Drug Profile

A 01 - IC 01

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hangzhou Converd
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 02 Apr 2018 Hangzhou Converd and The Second Hospital of Jia Xing plans a phase I trial for Gastrointestinal cancer (Combination therapy, Late-stage disease, In adults, In the elderly) in April 2018 (NCT03474861)
  • 21 Mar 2018 Hangzhou Converd in collaboration with The Second People's Hospital of Yibin plans a phase I trial of A 01 in combination with immune cells IC 01 for Solid Tumours (Late-stage disease) in China, in April 2018(NCT03472352)
  • 01 Mar 2018 Preclinical trials in Solid tumours (Late-stage disease) in China (unspecified route), before March 2018 (NCT03472352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top